latest
Market/Novel Tech Articles

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the exercise of an Allergan option to develop and commercialize “EDIT-101” – a CRISPR-based technology for the treatment of Leber Congenital Amaurosis type 10 (LCA10).  CRISPR (an acronym for “clustered regularly […]

Read full story

Novartis Q2 results emphasize transition to a full “100% medicines company”

Novartis AG (NYSE:NVS; SIX:NOVN), a Swiss-based biopharmaceutical company, has announced its second quarter results showing net sales of $13.2 billion for the period, of which net sales for ophthalmology products totaled $1.18 billion.  Novartis recently announced the sale of its stake in the GSK consumer healthcare joint venture for $13 billion, and its plan to […]

Read full story

Nightstar Therapeutics, a UK-based clinical stage gene therapy company, receives US FDA Regenerative Medicine Advanced Therapy (RMAT) designation

Nightstar Therapeutics (NASDAQ:NITE), originally a UK based spin-out of the University of Oxford, based on the founding work of Professor Robert MacLaren at the Nuffield Laboratory of Ophthalmology, has announced the receipt of Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA.  According to Nightstar, RMAT designation, established under the 21st Century Cures Act, […]

Read full story

Related Market/Novel Tech News